CSIMarket
 
Cardiff Oncology inc   (CRDF)
Other Ticker:  
 
 
Price: $5.0300 $-0.37 -6.852%
Day's High: $5.63 Week Perf: 24.5 %
Day's Low: $ 4.61 30 Day Perf: 189.08 %
Volume (M): 2,014 52 Wk High: $ 6.06
Volume (M$): $ 10,128 52 Wk Avg: $1.65
Open: $5.40 52 Wk Low: $0.94



 Market Capitalization (Millions $) 225
 Shares Outstanding (Millions) 45
 Employees -
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -23
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 1

Cardiff Oncology Inc
Cardiff Oncology Inc. is a biopharmaceutical company focused on the development of innovative cancer treatments. The company is based in San Diego, California, and is dedicated to improving outcomes for cancer patients. Cardiff Oncology's primary focus is on developing therapies that target solid tumors with significant unmet medical needs. The company utilizes its proprietary drug candidates and utilizes cutting-edge technology to identify potential solutions for cancer treatment. Their goal is to develop effective therapies that have minimal side effects and provide better treatment options for patients suffering from various types of cancer.


   Company Address: 11055 Flintkote Avenue San Diego 92121 CA
   Company Phone Number: 952-7570   Stock Exchange / Ticker: NASDAQ CRDF
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Advancements in Treatment: Cardiff Oncology Reports Positive Results and New Lead Program for RAS-Mutated mCRC

Published Thu, Feb 29 2024 9:07 PM UTC

In a recent announcement, Cardiff Oncology unveiled the results for the fourth quarter and full year of 2023, along with an exciting business update. The company reported substantial progress towards their new lead program in the treatment of RAS-mutated metastatic colorectal cancer (mCRC), made possible through collaboration with the FDA and clinical execution from Pfizer I...

Cardiff Oncology Inc

Despite Epic Surge in Revenue, Biotech Company Fails to Turn Profitable



Cardiff Oncology Inc (CRDF) has announced its financial results for the fiscal period ending September 30, 2023. The report indicates a significant increase in revenue, but also highlights a growing deficit. Comparisons with industry peers and previous reporting periods provide further context.
1. Revenue Growth:
Cardiff Oncology Inc experienced substantial revenue growth in the fiscal year ending September 30, 2023. Revenue elevated by an impressive 119.419% year on year, amounting to $1.21 million. Comparing this figure to the same period, the Biotechnology & Pharmaceuticals industry recorded an overall revenue elevation of 5.96%.

Cardiff Oncology Inc

Cardiff Oncology Inc. Achieves Remarkable Revenue Growth, Focusing on Profitability Amidst Impressive Results in Q1 2023

Cardiff Oncology Inc: A Strong Revenue Elevation Marks A Promising Future
Investors and shareholders of Cardiff Oncology Inc have reason to be excited as the company has announced a very solid revenue elevation of 1089.535% year on year to $1.02 million in the financial time-frame ending March 31, 2023. This presents a significant growth signal for the company that shows the potential to dominate the market.
Although there was an increase in the loss per share at $-0.25, compared to the previous reporting season which had an advanced loss per share of $-0.20, the company's revenue surged by 85.662% from $0.55 million. This is a clear indication that Cardiff Oncology Inc is on the right path to realizing its objectives as a leading player in the oncology industry.






 

Cardiff Oncology Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com